MPAN-18.1
NENCKIi003-A
General
Cell Line |
|
| hPSCreg name | NENCKIi003-A |
| Cite as: | NENCKIi003-A |
| Alternative name(s) |
MPAN-18.1
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 26th June 2024 |
| Notes | An iPSC cell line derived from dermal fibroblasts of a patient with mitochondrial membrane protein-associated neurodegeneration (MPAN), subtype of neurodegeneration with brain iron accumulation (NBIA). We generated and characterized four lines of human induced pluripotent stem cell (hiPSCs) derived from dermal fibroblasts of patients carrying homozygous mutation c.204_214del11, p.(Gly69Argfs*10) in the C19orf12 gene. |
| User feedback | |
Provider |
|
| Generator | Nencki Institute of Experimental Biology PAS (NENCKI) |
| Owner | Nencki Institute of Experimental Biology PAS (NENCKI) |
| Derivation country | Poland |
External Databases |
|
| BioSamples | SAMEA115779459 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 10-14 |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Non-disease associated phenotypes |
|
External Databases (Donor) |
|
| BioSamples | SAMEA115779466 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Please provide contact information of the holder of the original Donor Information Sheet. | Institute of Psychiatry and Neurology in Warsaw, Poland |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Alternatives to consent are available? | No |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Bioethics committee at the Institute of Psychiatry and Neurology in Warsaw |
| Approval number | 2/2022 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type | |
| Source cell origin |
Dermal fibroblasts are the major cell type in dermis and are commonly accepted as terminally differentiated cells.
|
| Age of donor (at collection) | 10-14 |
| Collected in | 2022 |
| Passage number reprogrammed | 3 |
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Lentivirus) |
| Genes | |
| Is the used vector excisable? |
Unknown |
| Absence of reprogramming vector(s)? |
Yes |
| Reprogramming vectors silenced? |
Yes |
| Methods used |
PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| SOX2 |
Yes |
|||||
| TRA 1-81 |
Yes |
Differentiation Potency
In vitro spontaneous differentiation
In vitro spontaneous differentiation
In vitro spontaneous differentiation
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.